Federal Circuit Cements Viatris Victory Over Biogen On Key US Tecfidera Patent
US Appeals Court Split 2-1; Analyst Predicts ‘Case Is Likely Concluded’
As anticipated by the street, Viatris has prevailed over Biogen on the originator’s appeal of a district court ruling that invalidated a key US patent shielding its Tecfidera treatment for multiple sclerosis. However, the Federal Circuit was not aligned on its decision.
